Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments
- Sponsor
- University Hospital Muenster
- Study ID
- NCT00976222
- Phase
- PHASE4
- Status
- Completed
Conditions
- Pigment Epithelial Detachment
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- intravitreal injection with ranibizumab — DRUG0.5 mg in 0.05 ml, monthly, 12 months
Study Details
The purpose of this study is to demonstrate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration (AMD).
Key Dates
- First listed
- Sep 14, 2009
- Start date
- Dec 31, 2008
- Status verified
- Sep 2017
- Primary completion
- Dec 31, 2014
- Completion
- Dec 31, 2015
Study Design
- Enrollment
- 40 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: 1 Arm Ranibizumab
Primary Outcome Measure
To investigate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration [ Time Frame: 12 months ]